Suven Life Sciences, a biopharma company focused on discovering, developing and commercializing novel pharmaceutical products, has presented clinical phase-I data for SUVN-502, its 5-HT6 antagonist drug candidate at the 2009 Alzheimer's Association International Conference on Alzheimer's disease in Vienna, Austria.
The details can be read here.
No comments:
Post a Comment